Worth reading
66In focus
Scored from 3 of 5 sectionsDirection
Neutral
Direction inferred from the company’s description.Scale
325000
SharesWording
Definitive
How definitive the wording is.Details of issuance or disposal
Issuance of Series 22 stock acquisition rights through a third-party allotment with an exercise price adjustment provision
発行・処分する株式数
Shares delivered during the month: 325,000 (325,000 new shares and 0 transferred treasury shares)
Intended allottee
EVO FUND (allottee at the time of issuance)
発行済株式総数
Exercise ratio subject to exercise restrictions: 0.7% (325,000 shares / 45,593,560 shares)
The dilution rate shows what proportion the newly issued shares represent of the existing shares. The higher the proportion, the more the value and voting rights per share are diluted.
Terms of the stock acquisition rights
Exercise price
Exercise price during the month: ¥27.00 or ¥28.00. Details of the exercise price adjustment clauses and the adjustment floor: Not disclosed.
Number of Stock Acquisition Rights
Total issued: 210,000; unexercised at the end of the month preceding the subject month: 107,910; unexercised at the end of the subject month: 104,660
Procedures under the Corporate Code of Conduct
The disclosure describes compliance with the exercise restrictions under Article 434 of the Listing Regulations
Most recent equity financing
Issued on 13 May 2026: Series 22 Stock Acquisition Rights with Exercise Price Adjustment Clauses, allocated to EVO FUND, Announced on 27 April 2026: Issuance by third-party allotment of Series 22 Stock Acquisition Rights with Exercise Price Adjustment Clauses and Series 2 unsecured bonds with stock acquisition rights (private placement bonds) (issue amount not disclosed)
| Item | Details |
|---|---|
| Type of issuance or disposal | Issuance of Series 22 stock acquisition rights through a third-party allotment with an exercise price adjustment provision |
| Number of shares to be issued or disposed of | Shares delivered during the month: 325,000 (325,000 new shares and 0 transferred treasury shares) |
| Intended allottee | EVO FUND (allottee at the time of issuance) |
| Dilution Rate | Exercise ratio subject to exercise restrictions: 0.7% (325,000 shares / 45,593,560 shares) |
| Total number of issued shares | 55,802,560 shares (as of the end of the month preceding the subject month) → Not disclosed |
| Exercise price | Exercise price during the month: ¥27.00 or ¥28.00. Details of the exercise price adjustment clauses and the adjustment floor: Not disclosed. |
| Number of Stock Acquisition Rights | Total issued: 210,000; unexercised at the end of the month preceding the subject month: 107,910; unexercised at the end of the subject month: 104,660 |
| Procedures under the Corporate Code of Conduct | The disclosure describes compliance with the exercise restrictions under Article 434 of the Listing Regulations |
| Most recent equity financing | Issued on 13 May 2026: Series 22 Stock Acquisition Rights with Exercise Price Adjustment Clauses, allocated to EVO FUND, Announced on 27 April 2026: Issuance by third-party allotment of Series 22 Stock Acquisition Rights with Exercise Price Adjustment Clauses and Series 2 unsecured bonds with stock acquisition rights (private placement bonds) (issue amount not disclosed) |
Items this document does not state (19)
Issue price and disposal priceTotal issue valueAmount of funds to be raisedEstimated issuance expensesSpecific use of fundsPayment dateIntended allottee's holding policyBasis for determining the amount to be paidExercise periodTransfer restriction periodConditions for lifting transfer restrictionsReason for acquisition without considerationCategories and Number of Persons CoveredTotal Stock-Based CompensationUnderwriter / lead underwriterOverallotmentStock Split RatioMajor shareholders after the offeringImpact on Business Performance
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To report the monthly exercise status of the Series 22 Stock Acquisition Rights for September 2026.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.